Literature DB >> 21139511

Primary percutaneous coronary intervention in 'early' latecomers with ST-segment elevation acute myocardial infarction: the role of the infarct-related artery status.

Alessandro Fontanelli1, Carlo Bonanno.   

Abstract

A high proportion of patients with ST-segment elevation myocardial infarction (STEMI) are evaluated more than 12 h after symptom onset. In this setting, current guidelines suggest that mechanical reperfusion should be considered for patients with clinical and/or electrocardiographic evidence of ongoing ischaemia, re-infarction, cardiogenic shock, haemodynamic instability, or documented ejection fraction less than 40% and serious ventricular arrhythmias. Moreover, some adjunctive aspects like the stuttering course of acute myocardial infarction, the chance of an existing coronary collateral circulation, the ischaemic preconditioning and the infarct-related artery patency should be taken into consideration for patients with STEMI presenting from 12 to 72 h after symptom onset. These patients are known as 'early' latecomers. The aim of the present review is to summarize the current knowledge of the pathophysiology related to this topic and to suggest some new indications for primary percutaneous coronary intervention in 'early' latecomers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21139511     DOI: 10.2459/JCM.0b013e32834038d8

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  2 in total

1.  Comprehensive Assessment of the Left Ventricular Systolic Function in the Elderly with Acute Myocardial Infarction Using Echocardiography.

Authors:  Xin Huang; Yuan Liu; Bo Guan; Wenyi Yang; Shasha Sun; Jiakun Luo; Yukun Luo; Jian Cao; Yujiao Deng
Journal:  Int J Gen Med       Date:  2022-02-11

2.  Late Percutaneous Coronary Intervention is Associated with Better Prognosis of Patients with Acute Myocardial Infarction.

Authors:  Hao Dong; Xuan Li; Dongping Xiao; Yong Tang
Journal:  Int J Gen Med       Date:  2022-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.